Related Topics News -

     
 Title only   |   Print    Next page > 
     
《大行》里昂料藥企增長勢頭持續 升翰森製藥康哲藥業目標價

2025-08-20T  
《大行》花旗:料中生製藥更多創新藥物上市 目標價升至10.8元 評級「買入」

2025-08-20T  
《大行》中金升中生製藥目標價至8.9元 中期業績勝預期

2025-08-20T  
《大行》中銀國際升中生製藥目標價至8.7元 維持「買入」評級

2025-08-20T  
《大行》Bernstein對中生製藥目標價更新至7.9元 創新藥業務興奮位有限

2025-08-20T  
《大行》交銀國際升中生製藥目標價至9.1元 維持「買入」評級

2025-08-20T  
中生製藥旗下創新藥LM-302納入突破性治療藥物程序

2025-08-19T  
《大行》野村:中生製藥中績大致符合預期 目標價升至9.17元

2025-08-19T  
中生製藥績後跌近半成 野村指中期業績大致符預期

2025-08-19T  
《大行》花旗升中生製藥目標價至10.5元 評級「買入」

2025-08-19T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.